NuVasive — Q3 2017 Earnings Presentation
15 slides from NuVasive's earnings presentation, Oct 24, 2017
Slide 1: Q3 2017 Results Supplemental Presentation to Earnings Press Release
Q3 2017 Results Supplemental Presentation to Earnings Press Release October 24, 2017 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements NuVasive cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could caus
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, non-cash purchase accounting adjustments on acq
Slide 4: Third Quarter 2017 Performance
Third Quarter 2017 Performance Reported year-over-year revenue growth of 3.2% to $247.4 million, or 3.4% on a constant currency basis. Delivered GAAP operating profit margin of 12.4%; non-GAAP operating profit margin of 17.6%, up 150 basis points from prior year. Drove GAAP diluted earnings per shar
Slide 5: Third Quarter 2017 Revenue Highlights
Third Quarter 2017 Revenue Highlights ~2% U.S. SPINAL HARDWARE Includes All Implants, Fixation, MAGEC® & PRECICE® ~(13)% ~46%* * Constant currency basis U.S. SURGICAL SUPPORT Includes Biologics, IOM Services & Disposables INTERNATIONAL Includes Puerto Rico Key Performance Factors Growth from new pro
Slide 6: Third Quarter 2017 Revenue Growth Rates
Third Quarter 2017 Revenue Growth Rates Percentage U.S. Spinal Hardware ~2% U.S. Surgical Support ~(13)% International* ~46% Q3 2017 Consolidated Growth Rate (reported) ~3% Estimated Impact of Hurricanes ~2% Estimated Impact of One Less Selling Day ~1% Q3 2017 Consolidated Growth Rate (adjusted) ~6%
Slide 7: Third Quarter 2017 P&L Performance
Third Quarter 2017 P&L Performance Non-GAAP Measures 3Q17 Actuals 3Q17 YoY Performance Factors Gross Margin 73.5% ↓ 280 bps negatively impacted by mix of revenue in lower margin businesses (~90 bps), a slower than anticipated ramp up in our in-sourced manufacturing (~70 bps), and timing of operation
Slide 8: Strong History of Growth and Profitability
Global Revenue (In Millions) Non-GAAP Operating Profit Margin ~$1,030* 11.4% 15.4% 16.1% ~16.6%* Strong History of Growth and Profitability DISCIPLINED EXECUTION OF STRATEGY DRIVES EXCEPTIONAL RESULTS Adjusted EBITDA (In Millions) ~17% CAGR ~520 Basis Points ~11% CAGR * NuVasive financial performanc
Slide 9: EXPANDING. Most Comprehensive Lateral Spine Surgery Portfolio
EXPANDING. Most Comprehensive Lateral Spine Surgery Portfolio. Access to L5-S1 via single position lateral surgery. Additive procedural solution to XLIF, providing increased access at L4-L5. Leading lateral fixation provides maximum access Delivering efficient, predictable clinical outcomes via LATE
Slide 10: ADVANCING. Technologies for the future
Proprietary Technology: Porous PEEK First-of-its kind porous architecture designed to promote superior bone in-growth, while maintaining the biomechanical and imaging properties of PEEK in general. Proprietary Technology: Modulus® Titanium Integrates endplate porosity with an optimized body lattice
Slide 11: Investing in Innovation
Investing in Innovation BUILDING WORLD-CLASS CENTERS OF EXCELLENCE SAN DIEGO, CALIFORNIA Expanding surgeon education lab for onsite surgeon training Building a prototype design facility with 3D-printing capabilities Developing state-of-the art biomedical testing center Building a world-class manufac
Slide 12: What Has Changed in our Assumptions
What Has Changed in our Assumptions PERFORMANCE THROUGH Q32017 HAS INFLUENCED OUR VIEWS What remains the same … What has changed … International revenue continues to grow 20%+ U.S. spine procedural volumes relatively flat Non-GAAP operating margin and EPS expansion Biologics weakness continues for n
Slide 13: FY17 Guidance
* NuVasive financial performance guidance as of October 24, 2017; ^Constant currency FY17 Guidance Performance Drivers Revenues As reported ~$1.030B ~7.2% YoY growth^ Including full year of Biotronic contribution; ~$2M currency headwind U.S. Spinal Hardware U.S. Surgical Support International ~3% Yo
Slide 14: Why Invest in NuVasive
Growing revenues at multiples of market in high single-digit range* Long-term non-GAAP operating profit margins expanding to ~25% and adjusted EBITDA margin to ~32%* Drive change in tax rate from high 30%’s to high 20%’s* Optimizing tax structure to drive EPS growth 2x the rate of revenue growth* Se
Slide 15: Slide 15